Concord Medical Services (CCM) AI Stock Analysis

• Market Cap: $17.63M
• Dividend Yield: N/A
• Average Volume (3M): 25.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.15
• Revenue Growth: -22.38%
• EPS Growth: 56.66%
• Country: US
• Employees: 595
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -9.83
• Shares Outstanding: 2,815,458
• 10 Day Avg. Volume: 72,657
• 30 Day Avg. Volume: 25,639
• PEG Ratio: >-0.01
• Price to Book (P/B): >-0.01
• Price to Sales (P/S): 0.01
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 207.02
• Enterprise Value/Revenue: 9.98
• Enterprise Value/Gross Profit: -87.20
• Enterprise Value/Ebitda: -10.18
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $4.50 ▼(-6.25% Downside)

The score is primarily weighed down by severe financial stress (declining revenue, persistent losses, negative equity, and negative operating/free cash flow). Technicals are only neutral and do not offset the weak fundamentals, while valuation is constrained by a negative P/E and lack of dividend support.

Positive Factors

Market Position

CCM's positioning as a leading provider of cancer treatment and diagnostics in China indicates durable demand and scale advantages. A broad network of centers supports referral flows, payer relationships and operational leverage that can sustain volume and service breadth over the medium term.

Advanced Treatment Capability

Specialization in IMRT and SRS represents a structural competitive edge: these technologies are high-complexity, require skilled staff and capital investment, create higher barriers to entry, and can attract referrals and premium reimbursements, supporting sustainable clinical differentiation.

Diversified Payer Mix

CCM's revenue sources include direct patient payments, government and private insurance reimbursements, and hospital partnerships. This payer and partner diversification reduces single-payer dependence, stabilizes billing streams, and supports predictable cash flow potential across reimbursement cycles.

Negative Factors

Revenue and Margin Erosion

A steep revenue decline combined with negative gross profit and EBIT margins undermines the business's ability to cover fixed costs and invest in equipment and personnel. Persistent top-line contraction threatens long-term scale economics and could force service reductions or restructurings.

Solvency Risk / Negative Equity

Negative shareholders' equity and liabilities exceeding assets indicate solvency strain. This structural balance-sheet weakness limits financing options, increases refinancing and covenant risk, and may necessitate asset sales, equity raises, or creditor negotiations that dilute long-term strategic flexibility.

Weak Cash Generation

Persistent negative operating and free cash flows signal chronic cash-generation problems, making the company reliant on external financing. Over months this constrains maintenance and replacement of capital-intensive radiotherapy equipment and limits investments needed to sustain clinical competitiveness.

Concord Medical Services Business Overview & Revenue Model

Company Description

Concord Medical Services Holdings Limited, together its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in two segments, Network and Hospital. Its services include linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, and diagnostic imaging services. The company's other treatments and diagnostic services comprise computed tomography scanners. In addition, it provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, the company offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, it operates specialty cancer hospitals, which offer radiotherapy services, diagnostic imaging services, chemotherapy, and surgery. As of December 31, 2021, it operated a network of 16 cooperative centers based in 13 hospitals. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.

How the Company Makes Money

Concord Medical Services generates revenue primarily through its cancer treatment services, including radiation therapy, diagnostic imaging, and related healthcare services. The company charges patients and insurance providers for these services, which often involve complex procedures and advanced technology. Key revenue streams include direct payments from patients, reimbursements from government health insurance programs, and private health insurance plans. Additionally, CCM may benefit from partnerships with hospitals and medical institutions, allowing for referrals and collaborative treatment plans, which can further enhance its revenue generation. The company's focus on expanding its network of treatment centers and leveraging technological advancements in cancer care also plays a crucial role in driving its profitability.

Concord Medical Services Financial Statement Overview

Summary

Very weak fundamentals: revenue fell sharply ($537M in 2023 to $384M in 2024), margins are negative (gross profit and EBIT), and net losses persist. The balance sheet shows solvency risk with negative stockholders’ equity and liabilities exceeding assets. Cash flow remains strained with negative operating and free cash flow, indicating reliance on external financing.

Income Statement

Concord Medical Services has experienced a persistent decline in revenue with a sharp drop from $537M in 2023 to $384M in 2024. Negative gross profit and EBIT margins indicate significant operational challenges. The net profit margin remains deeply negative, reflecting ongoing financial struggles.

Balance Sheet

The company's balance sheet shows considerable financial distress, with negative stockholders' equity reflecting a heavily leveraged position. The debt-to-equity ratio is not calculable due to negative equity, signaling high risk. Total liabilities exceed assets, indicating solvency issues.

Cash Flow

Cash flows are under pressure, with consistently negative operating and free cash flows. Despite a growth in financing cash flow, the reliance on external financing is unsustainable given the weak free cash flow to net income ratio, which remains negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	365.76M	383.96M	537.40M	472.08M	485.63M	223.01M
Gross Profit	-41.85M	-79.16M	-76.61M	-152.41M	-56.90M	13.08M
EBITDA	-358.51M	-345.62M	-344.16M	-401.86M	-363.86M	-236.72M
Net Income	-163.12M	-308.24M	-297.66M	-489.66M	-271.43M	-309.99M
Balance Sheet
Total Assets	6.73B	6.73B	6.05B	6.00B	6.23B	5.33B
Cash, Cash Equivalents and Short-Term Investments	177.39M	350.85M	58.14M	158.28M	157.39M	334.26M
Total Debt	3.82B	3.93B	3.30B	3.24B	2.73B	2.35B
Total Liabilities	5.01B	5.11B	4.31B	3.99B	3.49B	2.93B
Stockholders Equity	-2.24B	-2.28B	-2.12B	-1.86B	-1.37B	-662.96M
Cash Flow
Free Cash Flow	0.00	-808.58M	-392.17M	-600.47M	-1.12B	-734.47M
Operating Cash Flow	0.00	-397.75M	-276.47M	-216.69M	-359.31M	-229.77M
Investing Cash Flow	0.00	-593.44M	-47.68M	-118.79M	-565.98M	-533.88M
Financing Cash Flow	0.00	1.15B	257.65M	383.09M	642.45M	1.14B

Concord Medical Services Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCM, the sentiment is Negative. The current price of 4.8 is above the 20-day moving average (MA) of 4.51, above the 50-day MA of 4.21, and below the 200-day MA of 5.47, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.38 is Neutral, neither overbought nor oversold. The STOCH value of 26.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCM.

Concord Medical Services Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMS	51 Neutral	$13.92M	-6.26	-8.75%	―	17.84%	-156.13%
JYNT	49 Neutral	$145.39M	79.92	-1.37%	―	-54.93%	―
DCGO	47 Neutral	$74.98M	-1.49	-17.32%	―	-47.03%	-274.41%
PIII	45 Neutral	$13.83M	-0.04	-257.39%	―	-2.15%	-6.72%
CCM	44 Neutral	$17.63M	-0.75	―	―	-22.38%	56.66%
CCEL	44 Neutral	$26.74M	-57.09	―	11.14%	-0.29%	94.56%

Concord Medical Services Corporate Events

Concord Medical Announces 2025 Shareholder Meeting

On December 2, 2025, Concord Medical Services announced its 2025 annual general meeting of shareholders scheduled for December 29, 2025, in Beijing. The meeting will not involve any proposals for shareholder approval but will serve as a platform for shareholders to discuss company affairs with management. This event underscores Concord Medical’s commitment to transparency and stakeholder engagement, potentially impacting its operational strategies and market perception.

The most recent analyst rating on (CCM) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on Concord Medical Services stock, see the CCM Stock Forecast page.